Gene or Genome – Page 22

FDA to Reassess Use of PD-1 Inhibitors in Stomach Cancer, Seeking Expert Input on Merck, BMS, and BeiGene Medications

1 year ago talkbio0Tagged BeiGene, BMS, Burning Mouth Syndrome, Gene Expression, inhibitors, Merck, Oncologic, PD-L1, PD-L1, PDCD1 gene, United States Food and Drug Administration

FDA, PD-1 inhibitors, stomach cancer, Merck, BMS, BeiGene, Oncologic Drugs Advisory Committee, PD-L1 expression

Eli Lilly Unveils State-of-the-Art Genetic Medicine Research Center in Boston

1 year ago talkbio0Tagged City of Boston, ELAVL2 gene, Eli, Eli Lilly, genetic medicines, innovation

Eli Lilly, Boston, genetic medicines, research center, innovation hub, biotech

AstraZeneca Secures Landmark EU Approval for Imfinzi-Lynparza Combo in Endometrial Cancer Treatment

1 year ago talkbio0Tagged Approved, AstraZeneca, Combined Modality Therapy, EU, Imfinzi, Immunotherapy, Inhibitor, Lynparza, Malignant neoplasm of endometrium, Mismatch Repair, Mismatch Repair Deficiency, PARP1 gene, proficient

AstraZeneca, Imfinzi, Lynparza, endometrial cancer, EU approval, combination therapy, immunotherapy, PARP inhibitor, mismatch repair proficient, mismatch repair deficient

Galderma’s IL-31 Blocker Nemluvio Gains FDA Approval for Prurigo Nodularis

1 year ago talkbio0Tagged Approved, Blocker, Galderma, IL31 gene, Nemluvio, nodularis, Prurigo, United States Food and Drug Administration

Galderma, Nemluvio, IL-31 blocker, FDA approval, prurigo nodularis, therapeutic dermatology

Novartis Fails to Block MSN’s Entresto Generic Launch

1 year ago talkbio0Tagged Approved, Entresto, infringement, Legal patent, MSN gene, Novartis, United States Food and Drug Administration

Novartis, Entresto, MSN Pharmaceuticals, generic drugs, patent infringement, FDA approval

Galderma’s Nemluvio Receives FDA Approval for Prurigo Nodularis Treatment

1 year ago talkbio0Tagged Approved, chronic skin condition, Galderma, IL31 gene, Inhibitor, Nemluvio, Prurigo nodularis, Pruritus, United States Food and Drug Administration

Nemluvio, Galderma, FDA Approval, Prurigo Nodularis, IL-31 Inhibitor, Chronic Skin Condition, Itch Treatment

FDA Approves ARS’s Epinephrine Nasal Spray for Emergency Allergic Reactions

1 year ago talkbio0Tagged anaphylaxis, Approved, epinephrine, Epipen, Nasal Spray, needle-free alternative, SLURP1 gene, United States Food and Drug Administration

FDA approval, epinephrine nasal spray, ARS Pharmaceuticals, anaphylaxis treatment, needle-free alternative, EpiPen

FDA Criticizes Bristol Myers Squibb for Misleading Efficacy Claims on Krazati Website

1 year ago talkbio0Tagged Cancer Therapeutic Procedure, Claims, Effectiveness, K-ras Oncogene, KRAZATI, Myers, Non-Small Cell Lung Carcinoma, non-small-cell lung cancer, squibb, United States Food and Drug Administration

Bristol Myers Squibb, FDA, Krazati, misleading efficacy claims, non-small-cell lung cancer, NSCLC, KRAS G12C-mutated, cancer treatment

FDA Approves Servier’s Brain Cancer Drug, Triggering $1 Billion Payout for Agios

1 year ago talkbio0Tagged Agios, Approved, Blood - brain barrier anatomy, Brain Neoplasms, cancer metabolism, IDH1 gene, IDH2 gene, Mutation, payment, Royalty, Servier, United States Food and Drug Administration, Voranigo

FDA approval, Servier, brain cancer drug, Voranigo, Agios Pharmaceuticals, IDH1 and IDH2 mutations, blood-brain barrier, cancer metabolism, royalty payments

Stoke Therapeutics Advances Dravet Syndrome Drug to Phase III Trials After FDA Lifts Partial Clinical Hold

1 year ago talkbio0Tagged Activator, Infantile Severe Myoclonic Epilepsy, orphan drug designation, pediatric disease designation, Phase 3 Clinical Trials, SCN1A gene, Stoke, United States Food and Drug Administration, Zorevunersen

Stoke Therapeutics, Dravet syndrome, Phase III trials, FDA, zorevunersen, SCN1A activator, orphan drug designation, rare pediatric disease designation